Thiogenesis Therapeutics, Corp.
TTIPF
$0.42
-$0.03-6.67%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.19M | 1.17M | 1.22M | 1.08M | 1.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.97M | 5.31M | 5.00M | 3.76M | 2.97M |
| Operating Income | -4.97M | -5.31M | -5.00M | -3.76M | -2.97M |
| Income Before Tax | -5.00M | -5.33M | -4.89M | -3.64M | -2.75M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.00 | -5.33 | -4.89 | -3.64 | -2.75 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.00M | -5.33M | -4.89M | -3.64M | -2.75M |
| EBIT | -4.97M | -5.31M | -5.00M | -3.76M | -2.97M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.10 | -0.11 | -0.10 | -0.08 | -0.06 |
| Normalized Basic EPS | -0.06 | -0.07 | -0.06 | -0.05 | -0.04 |
| EPS Diluted | -0.10 | -0.11 | -0.10 | -0.08 | -0.06 |
| Normalized Diluted EPS | -0.06 | -0.07 | -0.06 | -0.05 | -0.04 |
| Average Basic Shares Outstanding | 200.11M | 194.30M | 188.18M | 183.59M | 182.78M |
| Average Diluted Shares Outstanding | 200.11M | 194.30M | 188.18M | 183.59M | 182.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |